---
title: A Cohort Study of Patients With Intracranial Hemorrhage
nct_id: NCT05760950
overall_status: UNKNOWN
sponsor: Capital Medical University
study_type: OBSERVATIONAL
primary_condition: Intracerebral Hemorrhage
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05760950.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05760950"
ct_last_update_post_date: 2023-03-09
last_seen_at: "2026-05-12T06:04:18.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Cohort Study of Patients With Intracranial Hemorrhage

**Official Title:** China Cohort of Patients With Intracranial Hemorrhage

**NCT ID:** [NCT05760950](https://clinicaltrials.gov/study/NCT05760950)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 300
- **Lead Sponsor:** Capital Medical University
- **Conditions:** Intracerebral Hemorrhage
- **Start Date:** 2020-12-11
- **Completion Date:** 2023-06-01
- **CT.gov Last Update:** 2023-03-09

## Brief Summary

As one of the most serious forms of acute stroke, the early mortality rate of intracerebral hemorrhage(ICH) can be as high as 30-40%. The incidence of intracerebral hemorrhage increases with the increase of age. Under the circumstance of the aggravation of aging in China, intracerebral hemorrhage brings a certain burden to families and society.

The results of several studies in recent years have failed to provide new therapeutic approaches for the treatment of cerebral hemorrhage. Therefore, novel therapeutic approaches is urgently needed for ICH. Primary and secondary prevention, acute inpatient care, and poststroke rehabilitation are all critical. The objective of this cohort study is to explore factors that might influence the long-term prognosis of patients with ICH and to further identify new potential targets for intervention.

## Detailed Description

The observational cohort study will be used to find the possible treatment methods and predictors of functional outcome. The medical records of patients will be collected, including age, sex, comorbid conditions, toxic habits, use of medications (antiplatelets, anticoagulants, and antihypertensives), systolic and diastolic blood pressure, Glasgow Coma Scale (GCS) score, and National Institutes of Health Stroke Scale (NIHSS) score on admission. Image data will also be collected. Follow-up information will be obtained from the medical records or telephone interviews.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Primary intracerebral hemorrhage
* Over 18 year-old

Exclusion Criteria:

* Secondary intracerebral hemorrhage, such as aneurysmal, hemorrhagic transformation of ischemic stroke, cavernomas, arterio-venous malformations, central venous thrombosis, trauma-related, or tumor.
* Pregnant patients.
* Any condition which, in the judgment of the investigator, might increase the risk to the patient.
```

## Interventions

- **Routine clinical treatment** (OTHER) — Routine clinical treatment is based on the latest international guidelines for intracerebral hemorrhage.

## Primary Outcomes

- **Functional outcome** _(time frame: 90-day)_ — evaluated by modified Rankin Scale

## Secondary Outcomes

- **Neurological deterioration** _(time frame: 14-day)_
- **Functional outcome** _(time frame: 1-year)_
- **Cerebrovascular disease event** _(time frame: 2-year)_

## Locations (1)

- Xuan Wu Hospital，Capital Medical University, Beijing, Beijing Municipality, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.xuan wu hospital，capital medical university|beijing|beijing municipality|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05760950.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05760950*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*